메뉴 건너뛰기




Volumn 41, Issue 11, 2014, Pages 2120-2128

A phase III, multicenter, randomized, double-blind, placebo-controlled, parallel-group study of 2 dosing regimens of fostamatinib in patients with rheumatoid arthritis with an inadequate response to a tumor necrosis factor-α antagonist

Author keywords

Efficacy oskira; Fostamatinib; Methotrexate; Rheumatoid arthritis

Indexed keywords

ADALIMUMAB; ALANINE AMINOTRANSFERASE; CERTOLIZUMAB PEGOL; ETANERCEPT; FOSTAMATINIB; GOLIMUMAB; INFLIXIMAB; METHOTREXATE; PLACEBO; OXAZINE DERIVATIVE; PYRIDINE DERIVATIVE; TUMOR NECROSIS FACTOR ALPHA;

EID: 84919378443     PISSN: 0315162X     EISSN: 14992752     Source Type: Journal    
DOI: 10.3899/jrheum.140238     Document Type: Article
Times cited : (49)

References (17)
  • 2
    • 77957344572 scopus 로고    scopus 로고
    • Healing the syk through kinase inhibitors
    • Rivera J, Colbert RA. Healing the Syk through kinase inhibitors. N Engl J Med 2010; 363:1362-4.
    • (2010) N Engl J Med , vol.363 , pp. 1362-1364
    • Rivera, J.1    Colbert, R.A.2
  • 3
    • 33645867986 scopus 로고    scopus 로고
    • A novel spleen tyrosine kinase inhibitor blocks c-jun N-terminal kinase-mediated gene expression in synoviocytes
    • Cha HS, Boyle DL, Inoue T, Schoot R., Tak PP, Pine P, et al. A novel spleen tyrosine kinase inhibitor blocks c-Jun N-terminal kinase-mediated gene expression in synoviocytes. J Pharmacol Exp Ther 2006; 317:571-8.
    • (2006) J Pharmacol Exp Ther , vol.317 , pp. 571-578
    • Cha, H.S.1    Boyle, D.L.2    Inoue, T.3    Schoot, R.4    Tak, P.P.5    Pine, P.6
  • 4
    • 77952249386 scopus 로고    scopus 로고
    • Contribution of gut bacteria to the metabolism of the spleen tyrosine kinase (Syk) inhibitor R406 in cynomolgus monkey
    • Sweeny DJ, Li W, Grossbard E., Lau DT. Contribution of gut bacteria to the metabolism of the spleen tyrosine kinase (Syk) inhibitor R406 in cynomolgus monkey. Xenobiotica 2010; 40:415-23.
    • (2010) Xenobiotica , vol.40 , pp. 415-423
    • Sweeny, D.J.1    Li, W.2    Grossbard, E.3    Lau, D.T.4
  • 5
    • 77953742534 scopus 로고    scopus 로고
    • Metabolism of fostamatinib, the oral methylene phosphate prodrug of the spleen tyrosine kinase inhibitor R406 in humans: Contribution of hepatic and gut bacterial processes to the overall biotransformation
    • Sweeny DJ, Li W, Clough J., Bhamidipati S, Singh R, Park G., et al. Metabolism of fostamatinib, the oral methylene phosphate prodrug of the spleen tyrosine kinase inhibitor R406 in humans: contribution of hepatic and gut bacterial processes to the overall biotransformation. Drug Metab Dispos 2010; 38:1166-76.
    • (2010) Drug Metab Dispos , vol.38 , pp. 1166-1176
    • Sweeny, D.J.1    Li, W.2    Clough, J.3    Bhamidipati, S.4    Singh, R.5    Park, G.6
  • 8
    • 78650294662 scopus 로고    scopus 로고
    • An oral syk kinase inhibitor in the treatment of rheumatoid arthritis: A three-month randomized, placebo-controlled, phase II study in patients with active rheumatoid arthritis that did not respond to biologic agents
    • Genovese MC, Kavanaugh A, Weinblatt M.E., Peterfy C., DiCarlo J, White ML, et al. An oral Syk kinase inhibitor in the treatment of rheumatoid arthritis: a three-month randomized, placebo-controlled, phase II study in patients with active rheumatoid arthritis that did not respond to biologic agents. Arthritis Rheum 2011; 63:337-45.
    • (2011) Arthritis Rheum , vol.63 , pp. 337-345
    • Genovese, M.C.1    Kavanaugh, A.2    Weinblatt, M.E.3    Peterfy, C.4    DiCarlo, J.5    White, M.L.6
  • 9
    • 0029044362 scopus 로고
    • American college of rheumatology. Preliminary definition of improvement in rheumatoid arthritis
    • Felson DT, Anderson JJ, Boers M, Bombardier C., Furst D, Goldsmith C, et al. American College of Rheumatology. Preliminary definition of improvement in rheumatoid arthritis. Arthritis Rheum 1995; 38:727-35.
    • (1995) Arthritis Rheum , vol.38 , pp. 727-735
    • Felson, D.T.1    Anderson, J.J.2    Boers, M.3    Bombardier, C.4    Furst, D.5    Goldsmith, C.6
  • 10
    • 0033984107 scopus 로고    scopus 로고
    • How to read radiographs according to the sharp/van der heijde method
    • van der Heijde D. How to read radiographs according to the Sharp/van der Heijde method. J Rheumatol 2000; 27:261-3.
    • (2000) J Rheumatol , vol.27 , pp. 261-263
    • Van Der Heijde, D.1
  • 11
    • 0036227149 scopus 로고    scopus 로고
    • How to report radiographic data in randomized clinical trials in rheumatoid arthritis: Guidelines from a roundtable discussion
    • van der Heijde D, Simon L, Smolen J, Strand V, Sharp J, Boers M, et al. How to report radiographic data in randomized clinical trials in rheumatoid arthritis: guidelines from a roundtable discussion. Arthritis Rheum 2002; 47:215-8.
    • (2002) Arthritis Rheum , vol.47 , pp. 215-218
    • Van Der Heijde, D.1    Simon, L.2    Smolen, J.3    Strand, V.4    Sharp, J.5    Boers, M.6
  • 12
    • 33645762226 scopus 로고
    • A sharper bonferroni procedure for multiple tests of significance
    • Hochberg Y. A sharper Bonferroni procedure for multiple tests of significance. Biometrika 1988; 75:800-2.
    • (1988) Biometrika , vol.75 , pp. 800-802
    • Hochberg, Y.1
  • 14
    • 0001669953 scopus 로고
    • A comparison of two modified bonferroni procedures
    • Hommel G. A comparison of two modified Bonferroni procedures. Biometrika 1989; 76:624-5.
    • (1989) Biometrika , vol.76 , pp. 624-625
    • Hommel, G.1
  • 15
    • 84908309209 scopus 로고    scopus 로고
    • OSKIRA-2: A phase III, multicenter, randomized, double-blind, placebo-controlled parallel-group study of 2 dosing regimens of fostamatinib in rheumatoid arthritis patients with an inadequate response to disease-modifying antirheumatic drugs [abstract]
    • Dawes P, Dimic A, Genovese M., van der Heijde D, Jenkins M, O'Brien C, et al. OSKIRA-2: a phase III, multicenter, randomized, double-blind, placebo-controlled parallel-group study of 2 dosing regimens of fostamatinib in rheumatoid arthritis patients with an inadequate response to disease-modifying antirheumatic drugs [abstract]. Arthritis Rheum 2013; 65 Suppl 10:S198.
    • (2013) Arthritis Rheum , vol.65 , pp. S198
    • Dawes, P.1    Dimic, A.2    Genovese, M.3    Van Der Heijde, D.4    Jenkins, M.5    O'Brien, C.6
  • 16
    • 84954349338 scopus 로고    scopus 로고
    • OSKIRA-4: A phase IIb randomised, placebo-controlled study of the efficacy and safety of fostamatinib monotherapy
    • Jul 29 (E-pub ahead of print)
    • Taylor PC, Genovese MC, Greenwood M, Ho M., Nasonov E, Oemar B, et al. OSKIRA-4: a phase IIb randomised, placebo-controlled study of the efficacy and safety of fostamatinib monotherapy. Ann Rheum Dis 2014 Jul 29 (E-pub ahead of print).
    • (2014) Ann Rheum Dis
    • Taylor, P.C.1    Genovese, M.C.2    Greenwood, M.3    Ho, M.4    Nasonov, E.5    Oemar, B.6
  • 17
    • 84912051613 scopus 로고    scopus 로고
    • Effects of fostamatinib, an oral spleen tyrosine kinase inhibitor, in rheumatoid arthritis patients with an inadequate response to methotrexate: Results from a phase III, multicenter, randomized, double-blind, placebo-controlled, parallel-group study
    • in press
    • Weinblatt ME, Genovese MC, Ho M, Hollis S., Rosiak-Jedrychowicz K, Kavanaugh A, et al. Effects of fostamatinib, an oral spleen tyrosine kinase inhibitor, in rheumatoid arthritis patients with an inadequate response to methotrexate: results from a phase III, multicenter, randomized, double-blind, placebo-controlled, parallel-group study. Arthritis Rheum 2014; in press.
    • (2014) Arthritis Rheum
    • Weinblatt, M.E.1    Genovese, M.C.2    Ho, M.3    Hollis, S.4    Rosiak-Jedrychowicz, K.5    Kavanaugh, A.6


* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.